Method for preparation of single chain antibodies
View Patent ↗This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.
1. A method for inducing proliferation in a population of lymphocytes, comprising the steps of:
(a) introducing an expressable gene sequence encoding a chimeric single chain antibody (scFv) coupled to a transmembrane domain and a signaling domain into a lymphocyte, wherein the scFv comprises the heavy and light chain variable regions of monoclonal antibody 8H9, and the transmembrane domain is derived from the transmembrane domain of CD28; and
(b) exposing the lymphocyte to an anti-idiotypic antibody that will bind to the chimeric scfv expressed on the surface of the lymphocyte, thereby inducing proliferation of the lymphocyte.
2. The method of claim 1 , wherein the lymphocyte is a peripheral blood lymphocyte.
3. The method of claim 1 , wherein the lymphocyte is a T cell or NK cell.
4. The method of claim 3 , wherein the T cell is a CD4 + T cell or CD8 + T cell.
5. The method of claim 1 , wherein the lymphocyte is obtained from a cancer patient.
6. The method of claim 1 , wherein the signaling domain is derived from the signaling domain of TCR-ζ chain.
7. The method of claim 1 , wherein the anti-idiotypic antibody is used ex vivo to activate a lymphocyte.